A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

Publication date: Feb 07, 2020

The purpose of this phase I/Ib study is to determine the safety profile of NIZ985 (new formulation), and if it can be safely combined with Spartalizumab and to determine the appropriate dose and schedule for further study. Moreover, the study will characterize the pharmacokinetic profiles of NIZ985 as a single agent and in combination with Spartalizumab and identify preliminary anti-tumor activity.

Concepts Keywords
Abstinence Chemotherapy
Acute Myocardial Infarction Antibodies
Adrenal Insufficiency Breast cancer management
Agonist Radiobiology
Alanine Transaminase Brain metastasis
Alopecia Chemotherapy
ALT Radioactivity
ANC Radiation therapy
Antibiotic Cancer treatments
Antibiotics Medicine
Antibodies Health
Antineoplastic Antiviral therapy
Antiviral Therapy Immunotherapy
Arrhythmia Experimental therapy
Aspartate Transaminase Antibiotic therapy
AST Chemotherapy
Autoimmune Disease Hormone replacement
Basal Immunosuppressive therapy
Bilirubin Major surgery
Biopsy Antibiotics
Bisphosphonate Hysterectomy
Carcinoma Periodic abstinence
Cardiovascular Radiotherapy surgery
Cardiovascular Disease Contraception
Cervical Antineoplastic therapy
Check Point Immunotherapies
Chemotherapy Vaccines infectious diseases
Chronic HBV Adrenal insufficiency
Common Preliminary anti tumor
Congenital Ototoxicity alopecia
Congestive Heart Failure Systemic antibiotics infection
Contraception Cervical tumors
Corticosteroids Malignant disease
CPI Skin rash
Cytotoxic Hormone replacement psoriasis
Diabetes Expansion escalation Infection
ECG Interstitial lung pneumonitis
Electrolytes Uncontrolled hypertension
Endocrinopathies Hypothyroidism
Estrogen HBV
Excipients HIV
Failure Rate Tumor
Feeding Tube
GHRH
Growth Factors
HBV
HCV
Hematopoietic
Histologically
HIV
Hormonal Contraception
Hormone
Hypersensitivity
Hypertension
Hypothyroidism
Hysterectomy
IL 15
Immunosuppressive Therapy
Immunotherapies
Immunotherapy
Infection
Infectious Diseases
Informed Consent
Interferon
Intrauterine Device
Intrauterine System
IUD
Japan
Kinase
Lactating
Lung
Lymphoma
Malignancies
Malignant
Melanoma
Metastases
Metastatic
Mitomycin
Msec
Nasal
NCI
Neuropathy
Novartis
Nursing
Oophorectomy
Ophthalmic
Ototoxicity
Ovulation
Palliative
Pharmacokinetic
Pneumonitis
Prednisone
Progesterone
Protocol
Psoriasis
Radiographic
Radiotherapy
Skin Rash
Squamous Carcinoma
Sterilization
Steroid
Steroids
Subcutaneously
Syndrome
Toxicity
Toxin
Transfusion
Tubal Ligation
Tumor
Unstable Angina
Vasectomized
Vitiligo
Washout

Semantics

Type Source Name
disease MESH lifestyle
disease MESH infectious diseases
disease MESH growth
drug DRUGBANK Somatotropin
drug DRUGBANK Somatorelin
drug DRUGBANK Denosumab
disease MESH ototoxicity
disease MESH alopecia
drug DRUGBANK Progesterone
disease MESH estrogen
drug DRUGBANK Mitomycin
disease MESH pneumonitis
disease MESH interstitial lung disease
drug DRUGBANK L-Alanine
disease MESH cervical cancer
disease MESH psoriasis
disease MESH hypothyroidism
disease MESH vitiligo
disease MESH autoimmune disease
disease MESH HIV infection
disease MESH Infection
disease MESH unstable angina
disease MESH myocardial infarction
disease MESH arrhythmia
disease MESH hypertension
disease MESH congestive heart failure
disease MESH heart disease
disease MESH cardiovascular disease
pathway KEGG Basal cell carcinoma
disease MESH basal cell carcinoma
disease MESH adrenal insufficiency
drug DRUGBANK Prednisone
disease MESH metastases
disease MESH hypersensitivity
drug DRUGBANK Methionine
disease MESH biopsy
disease MESH lymphoma
disease MESH tumor

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *